Literature DB >> 11007716

High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates.

J K Zubieta1, P Huguelet, L E Ohl, R A Koeppe, M R Kilbourn, J M Carr, B J Giordani, K A Frey.   

Abstract

OBJECTIVE: It has been hypothesized that anomalies in monoaminergic function underlie some of the manifestations of bipolar disorder. In this study the authors examined the possibility that trait-related abnormalities in the concentration of monoaminergic synaptic terminals may be present in patients with asymptomatic bipolar disorder type I.
METHOD: The concentration of a stable presynaptic marker, the vesicular monoamine transporter protein (VMAT2), was quantified with (+)[(11)C]dihydrotetrabenazine (DTBZ) and positron emission tomography. Sixteen asymptomatic patients with bipolar I disorder who had a prior history of mania with psychosis (nine men and seven women) and individually matched healthy subjects were studied. Correlational analyses were conducted to examine the relationship between regional VMAT2 binding, cognitive function, and clinical variables.
RESULTS: VMAT2 binding in the thalamus and ventral brainstem of the bipolar patients was higher than that in the comparison subjects. VMAT2 concentrations in these regions correlated with performance on measures of frontal, executive function. In addition, sex differences in VMAT2 binding were detected in the thalamus of the bipolar patients; the male patients had higher binding than the women. No sex differences in binding were observed in the healthy comparison group.
CONCLUSIONS: These initial results suggest that higher than normal VMAT2 expression and, by extension, concentration of monoaminergic synaptic terminals, may represent a trait-related abnormality in patients with bipolar I disorder and that male and female patients show different patterns. Also, VMAT2 concentrations may be associated with some of the cognitive deficits encountered in euthymic bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007716     DOI: 10.1176/appi.ajp.157.10.1619

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  22 in total

1.  The underlying neurobiology of bipolar disorder.

Authors:  Husseini K Manji; Jorge A Quiroz; Jennifer L Payne; Jaskaran Singh; Barbara P Lopes; Jenilee S Viegas; Carlos A Zarate
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

2.  Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition.

Authors:  Claudia J P Simons; Ruud van Winkel
Journal:  Schizophr Bull       Date:  2012-04-24       Impact factor: 9.306

3.  A tyrosine-based motif localizes a Drosophila vesicular transporter to synaptic vesicles in vivo.

Authors:  Anna Grygoruk; Hao Fei; Richard W Daniels; Bradley R Miller; Aaron Diantonio; David E Krantz
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

4.  Tackling the Kraepelinian Dichotomy: a Neuroimaging Review.

Authors:  Alan R Prossin; Melvin G McInnis; Amit Anand; Mary M Heitzeg; Jon-Kar Zubieta
Journal:  Psychiatr Ann       Date:  2010-03

5.  Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar i disorder.

Authors:  Falk W Lohoff; John P Dahl; Thomas N Ferraro; Steven E Arnold; Jürgen Gallinat; Thomas Sander; Wade H Berrettini
Journal:  Neuropsychopharmacology       Date:  2006-08-23       Impact factor: 7.853

6.  Visualizing pancreatic beta-cell mass with [11C]DTBZ.

Authors:  Norman Ray Simpson; Fabiola Souza; Piotr Witkowski; Antonella Maffei; Anthony Raffo; Alan Herron; Michael Kilbourn; Agata Jurewicz; Kevan Herold; Eric Liu; Mark Adam Hardy; Ronald Van Heertum; Paul Emerson Harris
Journal:  Nucl Med Biol       Date:  2006-10       Impact factor: 2.408

Review 7.  Localization and expression of VMAT2 aross mammalian species: a translational guide for its visualization and targeting in health and disease.

Authors:  Martin K-H Schafer; Eberhard Weihe; Lee E Eiden
Journal:  Adv Pharmacol       Date:  2013

Review 8.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Authors:  Kelly M Lohr; Shababa T Masoud; Ali Salahpour; Gary W Miller
Journal:  Eur J Neurosci       Date:  2016-09-02       Impact factor: 3.386

9.  Vmat2 heterozygous mutant mice display a depressive-like phenotype.

Authors:  Masato Fukui; Ramona M Rodriguiz; Jiechun Zhou; Sara X Jiang; Lindsey E Phillips; Marc G Caron; William C Wetsel
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

10.  VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination.

Authors:  P K Multani; R Hodge; M A Estévez; T Abel; H Kung; M Alter; B Brookshire; I Lucki; A H Nall; K Talbot; G A Doyle; F W Lohoff
Journal:  Neuroscience       Date:  2012-11-29       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.